PRGFX vs VOOV: 20% overlap
T. Rowe Price Growth Stock and Vanguard S&P 500 Value ETF share 19.7% of their portfolios by weight — computed as Σ min(wA, wB) over every holding both funds own.
Different holding dates. These holdings were published about 3 months apart — PRGFX as of 2026-03-31, the rest through 2026-06-30. Each fund is compared using its most recent file, so any trading in between shows up as a difference.
You would hold two tickers and get the diversification of 1.8. Two funds that shared nothing would score 2.0; two identical funds score 1.0.
Top shared holdings
PRGFX and VOOV hold 25 of the same securities. The ten contributing most to the overlap figure:
| Holding | in PRGFX | in VOOV | Δ |
|---|---|---|---|
| AAPL | 11.1% | 7.3% | 3.7% |
| AMZN | 4.9% | 3.8% | 1.1% |
| TSLA | 2.7% | 1.6% | 1.2% |
| V | 2.3% | 0.9% | 1.4% |
| COST | 0.8% | 1.4% | 0.6% |
| GE | 2.1% | 0.6% | 1.4% |
| MA | 1.9% | 0.5% | 1.4% |
| ORCL | 0.6% | 0.4% | 0.2% |
| DHR | 0.4% | 0.4% | 0.0% |
| TMO | 0.3% | 0.6% | 0.3% |
Where PRGFX and VOOV differ
Sector weights as a share of each fund, ordered by the size of the gap rather than the size of the sector — two funds that overlap heavily still usually diverge somewhere.
| Sector | PRGFX | VOOV | Δ |
|---|---|---|---|
| Information Technology | 48.2% | 20.5% | +27.7pp |
| Communication Services | 13.1% | 2.9% | +10.2pp |
| Financials | 5.1% | 15.3% | −10.2pp |
| Consumer Staples | 0.8% | 8.8% | −8.0pp |
| Energy | 0.0% | 6.6% | −6.6pp |
| Unclassified | 5.9% | 0.0% | +5.9pp |
| Industrials | 5.6% | 11.4% | −5.8pp |
| Health Care | 6.5% | 12.2% | −5.8pp |
Δ is PRGFX minus VOOV, in percentage points. Sector data is not published by every issuer, so “Unclassified” is a real category rather than a gap in the table.
What each fund holds alone
63.1% of PRGFX by weight, held in no part of VOOV.
78.0% of VOOV by weight, held in no part of PRGFX.
A large count with a small weight is the usual shape: the positions one fund adds are typically its smallest ones.
Concentration and cost
| PRGFX | VOOV | |
|---|---|---|
| Top 10 holdings | 62.8% | 23.8% |
| Positions held | 79 | 438 |
| Cost per $10,000 held, per year | $64 | $7 |
Cost is the expense ratio applied to $10,000; it excludes any brokerage commission, bid-ask spread or tax consequence. Figures are facts about the funds, not a suggestion about which to hold.
Frequently asked
How much do PRGFX and VOOV overlap?
PRGFX and VOOV overlap 19.7% by portfolio weight — moderate overlap. They share 25 holdings. The figure comes from current issuer holdings files (PRGFX as of 2026-03-31, VOOV as of 2026-06-30).
How is the overlap between PRGFX and VOOV calculated?
As the sum of the smaller weight in each fund, over every holding both funds own: Σ min(wA, wB). If PRGFX holds a stock at 6% and VOOV holds the same stock at 4%, 4% counts as shared. The result is bounded between 0% and 100%, and it is computed after looking through any fund-of-funds to the underlying holdings.
Is it redundant to hold both PRGFX and VOOV?
That depends on your goals — we state facts, not advice. At 19.7% overlap, each fund still contributes meaningfully distinct exposure.
What does PRGFX own that VOOV doesn't?
PRGFX holds 79 positions and VOOV holds 438; 53 of PRGFX's positions don't appear in VOOV at all, and they are 63.1% of PRGFX by weight.
You probably hold more than two funds
This page compares PRGFX and VOOV. Paste your whole portfolio — brokerage, 401(k), IRA — and see the overlap across every fund at once, plus what you actually own underneath them and your own Effective Funds number. Free, no account, nothing stored.
X-ray my portfolio — free →Watch PRGFX vs VOOV
We re-read both funds’ published holdings every weeknight. Leave an address and we'll tell you when what's inside actually changes.
Not sending yet — email alerts are built but switched off, and you'll be among the first when they turn on. No spam, one-click unsubscribe.
Related comparisons
Sources: issuer holdings files, PRGFX as of 2026-03-31, VOOV as of 2026-06-30. Weights are fractions of each fund. Diagnostics, not advice.